Treatment >  Radioimmunotherapy for
Other Subtypes and indications

Last update: 08/09/2010

TOPICS:

MCL and Aggressive Lymphoma | CLL / SLL | T-cell and Hodgkins | High-Risk / Transformed
Follicular - new types and indications
TOPIC SEARCH ~ Web

Here we link to study protocols investigating the safety and efficacy of RIT for indications beyond what RIT is already approved for.  

Each protocol will provide contact and location information.

Completed studies are included as these might be considered as Off-Protocol therapies.

 

 

MCL and Aggressive Lymphoma:

	Phase 1 Study of Radio-sensitization Using Bortezomib (Velcade) for Relapsed Mantle Cell or Aggressive Lymphoma Patients in Radioimmunotherapy http://bit.ly/cfOftA
	Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma http://bit.ly/bbba12
	Targeted Intensification Utilizing ZBEAM Followed by Autologous Stem Cell Transplantation (ASCT) in Patients With High-grade B-Cell Lymphoma (ZBEAM2)
	Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-Cell Lymphoma http://bit.ly/bxEC8Z
	Zevalin Twice in Aggressive Non-Hodgkin Lymphoma http://bit.ly/daY0cI

CLL / SLL:

Study Looking at Effectiveness of 131-Tositumomab (Bexxar) Consolidation for Patients With CLL or SLL http://bit.ly/cJQCV7

T-cell and Hodgkins lymphoma:

	Iodine I 131 Monoclonal Antibody BC8 (anti-cd45) and Autologous Stem Cell Transplant in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Treatment http://bit.ly/c2LbFW (Hodgkin lymphoma - Must have CD45+ cells adjacent to the Reed Sternberg cells)
	131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma http://bit.ly/9TQAW9

High risk b-cell lymphoma / transformed lymphoma:

	High Dose Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell NHL http://bit.ly/bO0uuF
	Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant http://bit.ly/awVp5H
	Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Lymphoma (completed) "The results from Phase 1/2 (RIT-I-000) and Phase 2 (RIT-II-001) studies of Tositumomab and Iodine I 131 Tositumomab (TST/I-131 TST) demonstrated that TST/ I-131 TST produced a high response rate in patients with chemotherapy-relapsed/refractory, low-grade or transformed low-grade Non-Hodgkin's Lymphoma (NHL). On the basis of these results this study was designed to compare the efficacy of TST/ I-131 TST to the last qualifying chemotherapy regimen in patients with chemotherapy-refractory, low-grade or transformed low-grade NHL."
	CpG 7909 (immune adjuvant), Rituximab, and Zevalin in Treating Patients With NHL That is Recurrent or Did Not Respond to Previous Treatment http://bit.ly/9efFdm
	Safety and Efficacy of 90Y Zevalin in Nonmyeloablative (mini) Transplantation for Lymphoid Malignancies http://bit.ly/diXeWj

Orbital b-cell lymphoma:

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma (completed)

Follicular -new type of RIT:

	Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma http://bit.ly/c80PPu
	Bexxar or Zevalin in Treating Patients With Non-Hodgkin's Lymphoma http://bit.ly/asKpWL (Not a new indication, but a test to compare efficacy and safety ... what a novel idea : )
	Rituximab, Combination Chemotherapy, and Zevalin in Treating Patients With Stage I or Stage II Lymphoma (completed)
	WM - Waldenstrom's Macroglobulinemia
	Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia (completed)

Other

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome http://bit.ly/cDGLxa

Resources

1. Clinical Trials Search PAL